Interface Biologics
ClosedInterface Biologics was founded in 2001, is headquartered in Toronto, Canada, and has $8.0M in recorded funding across 4 rounds.
- Headquarters
- Toronto
- Founded
- 2001
- Business Model
- B2B
- Total Funding
- $8.0M
- Last Round
- Series BJan 2015
- Rounds
- 4
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 4 funding rounds and 4 investors for this company. The full record is or through the API.
About
Interface Biologics is a Toronto-based biomaterials company, founded in 2001, that developed proprietary, nano-engineered surface-modification polymer technologies to improve the safety and performance of medical devices, including its Endexo platform used to reduce clot risk on implants. In 2019 the company sold its surface-modification business to Evonik, and its team went on to found the ophthalmic drug-delivery spinout Ripple Therapeutics in 2020.
Summary
Interface Biologics is a Healthcare company based in Toronto, Canada, founded in 2001. It has raised $8.0M in total across 4 rounds, most recently a Series B round in Jan 2015. Investors include BDC Venture Capital, DSM Venturing and MaRS Investment Accelerator Fund.
Funding History
Jan 2015
Sign up to see all 4 events
Funding: Venture Round through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/interface-biologics"><img src="https://indexed.vc/api/badge/company/interface-biologics" alt="Interface Biologics on Indexed.vc" width="260" height="76" /></a>